MK-6194
Sponsors
Merck Sharp & Dohme LLC
Conditions
Dermatitis, AtopicHealthyNon segmental vitiligoNon-segmental VitiligoSystemic Lupus ErythematosusUlcerative Colitis
Phase 1
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
CompletedNCT04924114
Start: 2021-10-14End: 2024-07-15Updated: 2025-08-29
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
CompletedNCT05450198
Start: 2022-08-08End: 2024-05-22Updated: 2025-06-05
MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)
CompletedNCT06649877
Start: 2023-03-20End: 2023-07-13Updated: 2024-10-21
A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)
CompletedNCT06821334
Start: 2024-04-23End: 2024-08-09Updated: 2025-02-12
Phase 2
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
TerminatedNCT06113328
Start: 2023-11-27End: 2025-07-30Updated: 2026-07-10
Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
TerminatedNCT06161116
Start: 2023-12-27End: 2025-07-30Updated: 2026-08-10
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo.
CompletedCTIS2023-503502-37-00
Start: 2024-01-24End: 2025-06-30Target: 33Updated: 2025-07-22
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus
CompletedCTIS2023-505520-61-00
Start: 2024-03-11End: 2025-06-30Target: 69Updated: 2025-07-23